The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen’s Alzheimer’s drug Aduhelm, which was “rife with irregularities,” a congressional report showed on Thursday.
https://www.pharmalive.com/wp-content/uploads/2020/07/Biogen-to-study-Spinraza-in-combination-with-2-million-Novartis-drug-Reuters-7-21-20.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-12-29 17:14:252022-12-30 10:05:48Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer’s drug